Multimodality therapy for NSCLC

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

5 Scopus citations


The standard therapy for patients with unrespectable stage III non-small-cell lung cancer (NSCLC) is the combination of chemotherapy and radiotherapy. Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains unclear. Targeted therapy has met limited success in the treatment of unselected patients with stage III NSCLC. New studies using induction therapy with erlotinib or crizotinib for molecularly selected patients and consolidation therapy with checkpoint inhibitors are currently ongoing, and the results are eagerly awaited.

Original languageEnglish
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Number of pages13
StatePublished - Jan 1 2016

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042


  • Chemoradiotherapy
  • Immunotherapy
  • Molecularly targeted therapy
  • Stage III NSCLC


Dive into the research topics of 'Multimodality therapy for NSCLC'. Together they form a unique fingerprint.

Cite this